All In Biotech

Drug Trial Radar · NCT01126970

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

A Double-Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects

Last checked: Nov 20, 2026Latest source record: May 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 486 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

486

Actual

Start

Apr 2010

Primary completion

Jan 2011

Study completion Feb 2011

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
May 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the steady-state trough concentrations of velneperit (S-2367), velneperit (S-2367) tert-butyl OH, and velneperit (S-2367) tert-butyl OH-O glucuronide following 400 mg of velneperit (S-2367) three times per day and 120 mg of orlistat, either combined or separate.

Conditions

  • Obesity

Interventions

  • Velneperit 400 mgDrug

    Velneperit 400 mg q.d.

  • Orlistat 120 mgDrug

    Orlistat 120 mg t.i.d

  • Orlistat PlaceboDrug

    Orlistat Placebo t.i.d.

  • Velneperit PlaceboDrug

    Velneperit Placebo q.d

  • Reduced Calorie DietOther

    Reduced calorie diet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint was the change from baseline in body weight (kg) over the 168-day (24-week) double-blind treatment period, where baseline body weight was defined as the last measurement prior to randomizationTime frame: 168 days (24 weeks)

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Santa Rosa, California

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Ponte Vedra, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Louisville, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Milford, Massachusetts

  • Site not named

    North Dartmouth, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Manlius, New York

  • Site not named

    Rochester, New York

  • Site not named

    Cary, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Greenville, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    New Braunfels, Texas

  • Site not named

    Renton, Washington

  • Site not named

    Wauwatosa, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.